Methods for reducing the risk of hypoglycemia
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/00
A61K-051/00
출원번호
UP-0927535
(2007-10-29)
등록번호
US-7678762
(2010-04-21)
발명자
/ 주소
Green, Daniel T.
Henry, Robert R.
출원인 / 주소
DiObex, Inc.
대리인 / 주소
Knobbe Martens Olson & Bear LLP
인용정보
피인용 횟수 :
22인용 특허 :
58
초록
Pharmaceutical compositions comprising glucagon can be administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia. Also provided are methods of administering glucagon so as to reduce the risk of hypoglycemia.
대표청구항▼
We claim: 1. A method for reducing a risk of an onset of hypoglycemia in a subject who is not experiencing hypoglycemia, said method comprising administering glucagon to said subject in an amount equivalent to a subcutaneous administration of glucagon at a rate of 2 to 16 ng of glucagon per kg of s
We claim: 1. A method for reducing a risk of an onset of hypoglycemia in a subject who is not experiencing hypoglycemia, said method comprising administering glucagon to said subject in an amount equivalent to a subcutaneous administration of glucagon at a rate of 2 to 16 ng of glucagon per kg of subject weight per minute. 2. The method of claim 1, wherein the rate is 4 to 16 ng of glucagon per kg of subject weight per minute. 3. The method of claim 1, wherein the subject has a blood glucose level of at least 70 mg/dl during the administering. 4. The method of claim 3, wherein the subject's blood glucose is at least 200 mg/dl. 5. The method of claim 1, wherein the glucagon is administered for at least six hours. 6. The method of claim 5, wherein said glucagon is a slow release formulation of glucagon. 7. The method of claim 1, wherein the glucagon is administered in a slow release formulation of glucagon and provides glucagon at a rate of 1 to 20 ng of glucagon per kilogram of subject weight per minute for 5 hours once administered to the subject. 8. The method of claim 1, consisting of subcutaneously administering glucagon to said subject in a dosage that provides glucagon to the subject at a rate of 2 to 20 ng of glucagon per kg of subject weight per minute. 9. The method of claim 1, wherein the glucagon is administered on a daily basis. 10. A method of reducing a risk of an onset of hypoglycemia in a non-hypoglycemic subject without inducing hyperglycemia, said method comprising administering glucagon in a dose equivalent to a subcutaneous administration of 2 to 16 ng of glucagon per kg of subject weight per minute of desired effectiveness. 11. The method of claim 10, wherein the glucagon is administered subcutaneously. 12. The method of claim 10, wherein the glucagon is administered intravenously. 13. The method of claim 10, wherein the glucagon is administered via a pump. 14. The method of claim 10, wherein said glucagon comprises a depot formulation of glucagon. 15. The method of claim 10, wherein the subject has a blood glucose level of at least 70 mg/dl during the administering. 16. A method of reducing a risk of hypoglycemia without inducing hyperglycemia, which method comprises: administering glucagon subcutaneously; wherein administration of glucagon occurs daily; wherein when said glucagon is administered the subject has a blood glucose level of at least 70 mg/dL and is not exhibiting hypoglycemic symptoms wherein said glucagon is administered subcutaneously in a dosage that provides 2 to 16 ng of glucagon per kilogram of subject weight per minute; and wherein said subcutaneous administration provides plasma glucagon levels that are sustained for 6 to 8 hours in the range of 100 to 200 pg/ml. 17. The method of claim 16, wherein the glucagon is administered subcutaneously at a rate of 4 to 16 ng of glucagon per kilogram of subject per minute. 18. The method of claim 16, wherein the subject is at risk for hypoglycemia because the subject is receiving a hypoglycemic agent. 19. The method of claim 18, wherein the hypoglycemic agent is selected from the group consisting of: an insulin sensitizer, a DPP IV inhibitor, a GLP 1 analog, an insulin secretagogue, sulfonylurea, acetohexamide, chlorpropamide, tolazamide, tolbutamide, glimepiride, glipizide, extended release glipizide, glyburide, micronized glyburide, meglitinide, nateglinide, repaglinide, a gastric inhibitory polypeptide, glucagon-like peptide-1; morphilinoguanide BTS 67582, a phosphodiesterase inhibitor, a succinate ester derivative, an insulin receptor activator, an insulin sensitizing biguanide, metformin, thiazolidinedione, troglitazone, pioglitazone, roziglitazone, a non-TZD peroxisome proliferator activated receptor -gamma agonist GL262570, an aipha-glucosidase inhibitor, acarbose, miglitoim, glucovance, a tyrosine phosphatase inhibitor, vanadium, a PTP- 1B inhibitor, an AMPK activator, a 5-aminoimidazole-4-carboxamide ribonucleoside, exendin, pramlintide acetate, D-Chiro-Inositol, an altered peptide ligand (NBI-6024), an anergix DB complex, a GABA inhibit, a melanocortin, a Glucose lowering agent (ALT-4037), an insulin mimic, an insulin-like growth factor-1, metoclopramide HCL, a motilide, and a GAG mimetic. 20. The method of claim 19, wherein the hypoglycemic agent comprises an insulin sensitizer.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (58)
Ellinwood ; Jr. Everett H. (3519 Tonbridge Way Durham NC 27707), Apparatus and method for implanted self-powered medication dispensing.
Nho Kwang (Highland Park NJ) Zalipsky Shmuel (Edison NJ) Davis Frank (El Cerrito CA), Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute.
Orsolini Piero (Martigny CHX) Heimgartner Frederic (Martigny CHX), Composition for the sustained and controlled release of medicamentous substances and a process for preparing the same.
Alan M. Ezrin ; Dominique P. Bridon CA; Darren L. Holmes CA; Peter G. Milner, Conjugate comprising an antinociceptive agent covalently bonded to a blood component.
Ekwuribe Nnochiri N. (Southfield MI), Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and m.
Oh, Jong Eun; Lee, Keon Hyoung; Park, Tae Gwan; Nam, Yoon Sung, Controlled drug delivery system using the conjugation of drug to biodegradable polyester.
Bombardieri Guiseppe (Via della Mendola ; 47 Roma ITX), Device for the automatic insulin or glucose infusion in diabetic subjects, based on the continuous monitoring of the pat.
McIvor, K. Collin; Cabernoch, James L.; Branch, Kevin D.; Van Antwerp, Nannette M.; Halili, Edgardo C.; Mastrototaro, John J., Glucose sensor package system.
Schneider Philip H. (2939A Cowley Way San Diego CA 92117) Weber William J. (520 W. Ellis Ave. Inglewood CA 90302) Massaro Thomas A. (1339 Hill Top Rd. Charlottesville VA 22903), Insulin infusion pump.
Bridon Dominique P.,CAX ; L'Archeveque Benoit,CAX ; Ezrin Alan M. ; Holmes Darren L.,CAX ; Leblanc Anouk,CAX ; St. Pierre Serge,CAX, Long lasting insulinotropic peptides.
Bridon, Dominique P.; L'Archeveque, Benoit; Ezrin, Alan M.; Holmes, Darren L.; Leblanc, Anouk; St. Pierre, Serge, Long lasting insulinotropic peptides.
Beaumont Kevin (San Diego CA) Young Andrew A. (San Diego CA), Methods and Compositions for treatment of diabetes mellitus, hypoglycemia & other conditions.
Krantz Alexander ; Ezrin Alan M. ; Song Yonghong, Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes.
Beaumont Kevin (San Diego CA) Young Andrew A. (San Diego CA), Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions.
Norris Kjeld (Hellerup DKX) Thim Lars (Gentofte DKX) Norris Fanny (Hellerup DKX) Hansen Mogens T. (Olstykke DKX) Moody Alister J. (Holte DKX), Process for preparing glucagon or fragments or derivatives thereof in yeast.
Orsolini Piero (Martigny CHX) Heimgartner Frdric (Martigny CHX), Process for the preparation of microspheres made of a biodegradable polymeric material.
Renirie Alexis C. M.,NLX ; Houben Richard,NLX ; van Leeuwen Frank,NLX, System and method for continuous monitoring of diabetes-related blood constituents.
Unger Evan C. (Tucson AZ) Fritz Thomas A. (Tucson AZ) Matsunaga Terry (Tucson AZ) Ramaswami VaradaRajan (Tucson AZ) Yellowhair David (Tucson AZ) Wu Guanli (Tucson AZ), Therapeutic delivery systems related applications.
DeBelser, David; Hetchler, Clinton Robert; Sours, David Pardee; Kersch, Michael Wade, Advanced step therapy delivery for an ambulatory infusion pump and system.
DiPerna, Paul M.; Brown, David; Rosinko, Mike; Kincade, Dan; Michaud, Michael; Nadworny, John; Kruse, Geoffrey A.; Ulrich, Thomas R., Infusion pump system with disposable cartridge having pressure venting and pressure feedback.
DiPerna, Paul M.; Brown, David; Rosinko, Mike; Kincade, Dan; Michaud, Michael; Nadworny, John; Kruse, Geoffrey A.; Ulrich, Thomas R., Infusion pump system with disposable cartridge having pressure venting and pressure feedback.
Verhoef, Erik T.; DiPerna, Paul M.; Rosinko, Mike; Williamson, Mark; Kruse, Geoffrey A.; Ulrich, Thomas R.; Lamb, Phil; Saint, Sean; Michaud, Michael; Trevaskis, William, Infusion pump system with disposable cartridge having pressure venting and pressure feedback.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.